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Multiple sclerosis (MS) is a chronic inflammatory dis-
ease of the CNS and has a varying disease course
as well as variable response to treatment. Bio-
markers may therefore aid personalized treatment.
We tested whether in vitro activation of MS pa-
tient-derived CD4+ T cells could reveal potential bio-
markers. The dynamic gene expression response to
activation was dysregulated in patient-derived CD4+
T cells. By integrating our findings with genome-
wide association studies, we constructed a highly
connected MS gene module, disclosing cell acti-
vation and chemotaxis as central components.
Changes in several module genes were associated
with differences in protein levels, which were
measurable in cerebrospinal fluid and were used to
classify patients from control individuals. In addi-
tion, these measurements could predict disease
activity after 2 years and distinguish low and high re-
sponders to treatment in two additional, indepen-
dent cohorts. While further validation is needed
in larger cohorts prior to clinical implementation,
we have uncovered a set of potentially promising
biomarkers.INTRODUCTION
Multiple sclerosis (MS), a chronic inflammatory disease of the
CNS, is a common cause of neurological disability in young
persons (Dendrou et al., 2015). The introduction of new treat-2928 Cell Reports 16, 2928–2939, September 13, 2016 ª 2016 The A
This is an open access article under the CC BY license (http://creativements has improved the situation for many patients, yet some
patients do not respond to a given treatment and treatments
are costly and associated with side effects, sometimes severe.
Thus, biomarkers for personalized treatment would be highly
beneficial (Derfuss, 2012). The development of biomarkers is
hampered by the heterogeneity and complexity of the disease
process in MS, in which the underlying disease mechanisms
reflect the interplay between a large number of genes and
their downstream targets. Accordingly, genome-wide associa-
tion studies (GWASs) have revealed a growing list of genes
associated with MS (Beecham et al., 2013). While subse-
quent genome-wide expression profiling of immune cells has
increased our functional understanding of disease mechanisms
in MS, these studies have so far not resulted in clinically useful
biomarkers (Comabella and Montalban, 2014; Kemppinen
et al., 2011).
Previous gene expression profiling studies in MS primarily
examined unstimulated cells, i.e., a ‘‘snapshot’’ of how the
cells appear in vivo, where most cells are not stimulated.
We hypothesized that the dynamic response to activation
would reveal disease-associated pathways that were not
found during conventional profiling of blood cells. We there-
fore examined gene expression in unstimulated as well as in
stimulated cells, with the goal of identifying relevant genes
that might translate into clinically valuable biomarkers. We
focused our attention on CD4+ T cells because (1) they are
early and important regulators of adaptive immunity (Sallusto,
2016), (2) substantial evidence implicates peripherally acti-
vated CD4+ T cells in MS pathogenesis both in humans (Den-
drou et al., 2015; Fletcher et al., 2010; Okuda et al., 2005;
Putheti et al., 2003) and in animal models (Fletcher et al.,
2010), and (3) the association of MS with the CD4+ T cell-spe-
cific antigen-presenting molecule HLA Class II (DRB1*15:01) is
well established, as well as the more recent identification ofuthor(s).
commons.org/licenses/by/4.0/).
Figure 1. Overview of the Study
The figure shows the principle of the different analyses performed in the study.
(A) CD4+ T cells from both MS patients and controls were cultured in vitro for 24 hr in the presence or absence of 0.03 mg/ml anti-CD3 and anti-CD28 antibodies.
After mRNA isolation and microarray analysis of gene expression levels, three different datasets of differentially expressed genes between patients (n = 14) and
controls (n = 14) were generated, as follows: (1) in unstimulated CD4+ T cells, (2) in stimulated CD4+ T cells, and (3) the dynamic response dataset represented by
the unstimulated expression subtracted from the stimulated expression.
(B) Datasets were overlapped with MS-associated genes identified from GWAS and analyzed for enrichment to validate relevance for MS.
(C) The average distance in the protein-protein interaction network between random genes and the MS-associated genes present in the dynamic response
dataset was calculated.
(D) The dynamic response dataset was used to construct a module, which was further dissected into submodules with similar biological function.
(E) Four genes, selected from the module, and their corresponding proteins were measured in supernatants of stimulated and unstimulated CD4+ T cells as well
as in cerebrospinal fluid (CSF) from MS patients and controls. The combined score of these proteins was used to separate patients from controls and predict
evidence of disease activity within 2-year follow-up as well as response to treatment in three different cohorts of MS patients.several other T cell-associated genes in large GWASs of MS,
such as the interleukin (IL)-2 receptor alpha chain, the IL-12
receptor, and IL-7 (Sawcer et al., 2011; Patsopoulos et al.,
2011).
By combining traditional analysis of differential gene expres-
sion in stimulated CD4+ T cells with a network-based modular
approach, we found that aberrant dynamic response (DR)
genes, i.e. genes behaving differently upon stimulation in pa-
tients than in control individuals, were highly enriched for MS
genes, as defined by GWAS data (Sawcer et al., 2011). The
aberrantly expressed genes were associated with immune
activation and chemotaxis and a set of them encoded secreted
proteins (chemokine [C-X-C motif] ligand 1-3 [CXCL1-3],
CXCL10, chemokine [C-C motif] ligand 2 [CCL2], and osteopon-
tin [OPN]). A combination of these proteins, as measured in ce-
rebrospinal fluid (CSF), readily classified patients and controls
and, in two new cohorts, predicted 2-year disease activity in
early MS as well as response to treatment, respectively.RESULTS
Stimulation of CD4+ T Cells Reveals Differently
Expressed Genes Enriched for MS-Associated GWAS
Genes
The principal workflow of the study was as follows: identifying
genes that were dysregulated in isolated and activated CD4+
T cells from MS patients (Figure 1A); investigating whether the
identified genes were known to be associated with MS (Fig-
ure 1B); identifying functional relationships of the dysregulated
genes (Figures 1C and 1D); and testing whether this information
might be useful for identifying biomarkers in new cohorts of MS
patients (Figure 1E). To assess gene expression dynamics in
CD4+ T cells, we used an in vitro model, in which isolated
CD4+ T cells were cultured unstimulated or with commonly
used combined activation through the TCR (anti-CD3) and co-
stimulatory CD28 receptor (anti-CD28) (Sharpe and Freeman,
2002). We used a moderate level of stimulation, as measuredCell Reports 16, 2928–2939, September 13, 2016 2929
Table 1. Characteristics of the MS Cohorts
Controlsa MS
Study Cohort
n 16 16
Relapsing remitting (n) 16
Median age, years (range) 41.5 (27–51) 40.5 (26–52)
Sex (M/F) 0/16 0/16
Median disease duration,
years (range)
9.5 (0–17)
Annual relapse rate (mean)b 0.4
Median EDSS (range) 2.5 (0–7)
Median MSSS (range) 2.37 (0.09–9.21)
Previous treatmentc
Natalizumab 8
Fingolimod 1
IFN-b 4
Intravenous immunoglobulins 2
No previous treatment 1
Early MS Cohortd
n 11 41
Possible MS 19
Relapsing remitting (n) 22
Median age, years (range) 30 (22–47) 31 (21–62)
Sex (M/F) 2/9 9/32
Median disease duration,
months (range)
3.5 (0.3–120)
No previous treatment 41
Response to Treatment Cohorte
n 15
Median age, years (range) 34 (25–46)
Sex (M/F) 12/3
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; MSSS,
MS severity score. M, male; F, female.
aControls in both cohorts consisted of blood donors or employees at
Linko¨ping University Hospital. All controls were free from disease, and
medication and the controls in the early MS cohort had normal CSF find-
ings and no evidence of neurological disease.
bCalculated over 2 years prior to sampling.
cNone of the patients had received immunomodulatory or immunosup-
pressive treatment for at least 2months prior to sampling, with the excep-
tion of one patient who received intravenous immunoglobulin that was
stopped 15 days before sampling.
dConsecutively included when first seeking medical attention at the
Department of Neurology, Linko¨ping University Hospital, and fulfilling
criteria of clinical isolated syndrome (CIS) or relapsing-remitting (RR)
MS according to the revised MacDonald criteria from 2010 (Polman
et al., 2011).
eThis cohort was described previously (Gustafsson et al., 2014; Meller-
ga˚rd et al., 2010, 2013).by CD69 surface expression (Figure S1), a marker of global T cell
co-stimulation and activation. Gene expression profiling (22,610
genes) was performed on unstimulated and stimulated CD4+
T cells from a cohort of patients (n = 14; Table 1) with relaps-
ing-remitting MS, without treatment prior to the sampling occa-2930 Cell Reports 16, 2928–2939, September 13, 2016sion, as well as cells from matched control subjects (n = 14;
Table 1). In addition, to assess the dynamic response to stimula-
tion, we calculated the changes in gene expression. This was
done by subtracting expression in unstimulated cells from
expression in the stimulated cells in both patient and control
cells (unlogged data were used). The groups were thereafter
compared statistically, i.e. the change in gene expression upon
activation was compared between patients and controls. We
refer to these genes as dynamic response (DR) genes. When
comparing patients and controls using an unpaired t test (unad-
justed double-sided p < 0.05), we identified nominally differen-
tially expressed genes in unstimulated CD4+ T cells (n =
2,075), stimulated CD4+ T cells (n = 1,250), and DR genes ((stim-
ulated)  (unstimulated), n = 932)). However, when adjusting for
genome-wide testing (at 20% Benjamin Hochberg false discov-
ery rate), no genes were differentially expressed in any of the
three gene lists (unstimulated, stimulated, and DR). We thus dis-
placed the single gene analysis and proceeded by analyzing
groups of genes, starting by testing whether any of the lists
were enriched for genes relevant to MS. By assessing original
GWAS data from the International MS Genetic Consortium
(Sawcer et al., 2011) based on 25,000 patients and controls,
and by using a moderate stringency cut off (p < 105), we
identified 760 MS-associated SNPs that mapped, through the
closest transcription start site, to 216 unique genes (hereafter
referred to as MS genes; Table S1). To investigate whether our
three gene lists with differently expressed genes (unstimulated,
stimulated, and DR) actually contained genes that were associ-
ated with MS (as defined by previous GWASs), we overlapped
the three gene lists with the 216 MS genes and computed statis-
tical enrichment using Fisher’s exact test (Figures 1B and 2). The
highest fold enrichment (FE) of MS genes was found for the DR
genes (FE = 2.08, n = 19, p = 2.0 3 103; Figure 2). These 19
genes are referred to as MS-DR genes. Unstimulated CD4+
T cells showed a significant, but smaller, fold enrichment (FE =
1.65, n = 44, p = 5.3 3 104; Figure 2), while the stimulated
gene set showed no enrichment (FE = 0.93, n = 14, p = 0.648;
Figure 2) of GWAS genes (Table S1). While the unstimulated
gene set also included a high proportion of GWAS genes, we
decided to perform subsequent analyses using the DR genes,
since the primary objective of the study was to investigate dys-
regulated genes upon activation of CD4+ T cells from MS pa-
tients. To rule out the possibility that the GWAS genes found
among the DR genes were not generally associated with autoim-
mune disease, but specific toMS, we calculated the FE of GWAS
genes from two other autoimmune diseases, rheumatoid arthritis
(RA) and type I diabetes (T1D). For RA, we analyzed around
2,500,000 SNPs (Stahl et al., 2010) and found 81 genes at amod-
erate stringency cut off (p < 105). Only four of these RA-associ-
ated genes were found among the DR genes (FE = 1.16, p =
0.46). For T1D, about 500,000 SNPs were analyzed (Barrett
et al., 2009), of which 109 genes were considered to be associ-
ated with this disease (p < 105). Only two of these T1D-associ-
ated genes were found among the DR genes (FE = 0.43, p =
0.95). Taken together, genes that were differentially expressed
during in vitro activation of CD4+ T cells from MS patients, rep-
resenting the dynamic response to stimulation, were highly asso-
ciated with MS-relevant genes, as defined by GWASs.
Figure 2. Dynamic Response Genes Are Highly Enriched for MS-
Associated Genes
(A and B) Three datasets were generated by gene expression profiling of
isolated CD4+ T cells from MS patients (n = 14) and controls (n = 14), as fol-
lows: (1) differentially expressed genes in unstimulated cells, (2) stimulated
cells, and (3) the dynamic response to stimulation, defined as the expression
in stimulated cells subtracted by the expression in the unstimulated cells
(unpaired t test, unadjusted p < 0.05). (A) The genes in these three datasets
were overlapped with the 216 MS-associated genes (as defined by GWAS),
and (B) fold enrichment was calculated using Fisher’s exact test. See also
Table S1.Dynamic Response Genes Co-localize in the PPI
Network
It is known that proteins encoded by MS-associated genes
are more likely to be connected in the protein-protein interac-
tion (PPI) network (International Multiple Sclerosis Genetics
Consortium, 2013), thereby suggesting a functional relation-
ship. We therefore examined whether the 19 MS-DR genes
identified herein were also functionally related (Figure 1C).
To test this we used all high confidence human protein inter-
actions (n = 413,896) from among 14,543 proteins (STRING
database v.10 [Szklarczyk et al., 2015]). Analyzing this
network showed that most of the MS-DR genes were co-
localized in a neighborhood with a significantly shorter dis-
tance, compared to randomly equally sized sets of proteins
(harmonic average < d > = 2.9 versus < drand > = 5.2; permu-
tation test p = 2.0 3 103), where distance is defined as the
smallest number of interacting proteins between two given
genes. This analysis suggests a functional relationship be-
tween the MS-DR genes.A Module-Based Approach Reveals a Network of
Dysregulated Dynamic Response Genes with
Chemotaxis and Immune Regulation as Central
Components
The observed co-localization of MS-DR genes, together with the
fact that the DR gene list was enriched for MS-associated genes,
motivated us to use a network-based modular approach to
further search for functionally related genes among the 932 DR
genes with the purpose of finding the most interconnected DR
genes and their most interactive proteins (Figure 1D). A modular
approach means that we include both gene products that are
physically interconnected in the protein network, as well as other
tightly interconnected gene products (see Experimental Proced-
ures). These module genes are likely to be functionally related in
cellular processes and are thus considered to belong to a dis-
ease module. The resulting MS module contained 75 protein-
coding genes that differed significantly between patients and
controls (Figures 3A and 3B) and corresponded to proteins
involved in similar biological processes. To further elucidate
whether the module was associated with MS, we tested whether
these 75 genes overlapped with the MS genes that were identi-
fied using GWAS data. As shown in Figure 3C, the module was
highly enriched for MS genes (FE = 7.26, n = 7, Fisher’s exact
test, p = 5.0 3 105), thereby confirming that the module was
relevant for MS. To understand the biological function of this
module, we performed a gene ontology (GO) analysis using
DAVID (Huang et al., 2009) and defined five submodules based
on their localization within the module. The two larger submod-
ules contained significant enrichment of several GO terms
related to cell activation and chemotaxis (Table S2). In addition
to the MS-associated genes identified by GWASs, the module
contained both well-known genes previously linked to MS,
such as SPP1 (encoding for OPN) (Bo¨rnsen et al., 2011; Shimizu
et al., 2013) and TNFRSF1A (Gregory et al., 2012), as well as
less-studied genes of interest, such asNTF3 and several chemo-
kine genes. Collectively, by integrating GWAS and expression
profiling data and by using a modular approach to genes that
differed in their dynamic response to stimulation, we identified
a gene network of potential relevance to MS. The dominating
modules contained genes involved in intracellular signaling and
chemotaxis, and both well-known and less-explored biomarker
candidates were represented.
Module Proteins in Cell Culture Supernatants Are Able
to Classify Patients versus Controls
Since proteins measurable in fluids are most suitable as bio-
markers, we investigated whether the observed differences in
gene expression between patients and controls could be asso-
ciated with differences in protein expression. A total of six pro-
teins were selected from the two main submodules (Figure 3)
based on whether the protein was (1) known to be a secreted
product, (2) associated with CD4+ T cells, and (3) possible to
measure by commercial ELISA or multiplex bead technology.
Next, we measured the selected proteins (CCL2, CXCL1-3,
CXCL10, OPN, neurotrophin [NT]-3, and soluble tumor necrosis
factor receptor 1 [sTNFR1]; Table S3) in supernatants collected
from unstimulated and stimulated CD4+ T cells from MS pa-
tients (n = 16) and healthy controls (n = 16). The supernatantsCell Reports 16, 2928–2939, September 13, 2016 2931
Figure 3. A Dynamic Response Module Reveals Chemotaxis and Cell Activation as Central Components
(A–C) The 932 dynamic response (DR) genes, which responded differently between patients and controls upon T cell activation, were used to construct a module
of the most interconnected DR proteins, by combining it with the human PPI database STRING.
(A) The figure shows the 75 genes included in the module and their individual interactions, where GWAS genes are indicated with red rings. The module was
further dissected into biologically relevant submodules using DAVID GO analysis, where the two main submodules (‘‘Chemotaxis’’ and ‘‘Cell activation’’) con-
tained statistically significant GO terms.
(B) Heatmap showing the dynamic response (expression levels of stimulated cells expression levels of unstimulated cells) of individual genes in the submodules
in patients and controls.
(C) The graph shows the fold enrichment (using Fisher’s exact test) of MS-associated GWAS genes among the 75 module genes as well as the fold enrichment in
the original dynamic response (DR) dataset (shown previously in Figure 2).
See also Table S2.were obtained from the same primary cohort in which gene
expression was analyzed. As with the dynamic gene expression
data, protein levels were defined as the difference in concentra-
tion between stimulated and unstimulated cells (referred to as
DR protein levels; Figure S2). In line with the gene expression
data, there was a significant increase in the levels of OPN
(Mann-Whitney test, p = 0.007) and a tendency toward an in-
crease in CXCL1-3 (p = 0.09) and CXCL10 (p = 0.08) in patient
samples, while no difference was observed in the levels of
CCL2 (p = 0.39). NT-3 and sTNFR1 were undetectable in all
samples.2932 Cell Reports 16, 2928–2939, September 13, 2016To see if the secreted protein levels after stimulation of CD4+
Tcellscoulddistinguishpatients fromcontrols inourprimary study
cohort,weused theDRprotein levelsand tested theability of a sin-
gle protein or the combination of the four proteins to classify pa-
tients and controls. As a combined disease score, the protein
levels of OPN, CXCL1-3, and CXCL10 were added, while the
CCL2 protein level was subtracted. We found that the sum of all
fourproteinscoulddiscriminatepatientsandcontrolswithhighac-
curacy (area under the curve [AUC] = 0.84, Mann-Whitney test p =
0.0013;Figure4A),whereasusinga singleprotein or combinations
of two or three proteins resulted in poorer discrimination (Table
Figure 4. Secreted Proteins from the Module Can Be Used to Construct a Combined Protein Score, which Discriminates Patients from
Controls and Predicts Disease Activity and Response to Treatment
(A–D) Each subplot represents discrimination of different cohorts, where the top panel depicts boxplots (boxes show the interquartile range and whiskers show
the total range) of the combined score and the lower panel represents receiver operating characteristic (ROC) curves.
(A) The combined score from secreted proteins in supernatants defined by (CXCL1-3) + (CXCL10) + (OPN) (CCL2) discriminated patients (n = 16) from controls
(n = 16) with high accuracy (AUC = 0.84, Wilcoxon rank test p = 0.0013). Each of the four selected proteins was defined by the difference between the stimulated
and unstimulated levels in cultures of CD4+ T cells.
(B) A combined protein score in CSF, defined from the probability computed by leave-one-out cross-validation and logistic regression of the four proteins
measured in CSF was able to discriminate early MS patients (n = 41) from controls (n = 11) in a new cohort with high accuracy (AUC = 0.79, p = 3.8 3 103).
(C) The combined score in CSF also discriminated between subgroups of MS patients who showed signs of disease activity (n = 27) from those with no evidence
of disease activity (NEDA, n = 12) at 2-year follow-up (AUC = 0.84, p = 9.6 3 104).
(D) The CSF score discriminated also, in an independent cohort, between high (n = 6) and low (n = 9) responders to natalizumab treatment with high accuracy
(AUC = 0.89, p = 0.012).
See also Table S4 and Table S5.S4), asdidmRNA levels obtained from the expressiondata (AUC=
0.71, p = 0.063). As a control classifier we constructed a similar
combined score by measuring eight other secreted proteins in
the same supernatants (granulocyte macrophage colony-stimu-
lating factor [GM-CSF], interferon [IFN]-g, IL-10, IL-13, IL-17,
CCL17, macrophage colony-stimulating factor [M-CSF], and
CCL20; Table S3) that were not part of the module, but are of
immunological relevanceandknown tobeaffectedbystimulation.
The 1,000 random combined scores created from the DR protein
levels from this set of 8 control proteins (mean AUC = 0.54) were
outperformed by the combined score from our selected module
proteins (p = 4.383 105, FE = 1.55). Taken together, the increase
in gene expression of the selected module genes was associated
with an increase in protein secretion, and by considering the
secreted levels of a combination of proteins in the supernatants
we were able to classify patients from healthy controls.
Module Proteins in Cerebrospinal Fluid Are Able to
Predict Disease Activity after 2 Years
Encouraged by the possibility of classifying patients from con-
trols based on protein levels after stimulation of CD4+ T cells,we asked if a combined score of proteins could serve as a
biomarker in MS (Figure 1E). To become a useful biomarker, it
would be advantageous if the proteins could be measured
in vivo, i.e. as soluble proteins in plasma or CSF. Of note, these
levels would indirectly reflect the dynamic response in vivo, as an
increase is probably caused by cell activation. This is particularly
pertinent to CSF, where disease-associated, activated T cells
are highly enriched. To test biomarker potential in a clinical
setting, we used a second, independent cohort of early MS
patients (Table 1) and measured the four proteins in CSF and
plasma samples obtained when patients first sought medical
attention. Since CSF cells could not be activated, as performed
for CD4+ T cells, and a dynamic response could therefore not be
formed, we inferred their relations in CSF. We performed logistic
regression of the four proteins in CSF from patients (n = 41)
versus healthy controls (n = 11) and estimated the predictive
value by computing the probability by leave-one-out cross-vali-
dation in order to assess the prediction error (Table S5). Interest-
ingly, the relationships among the four proteins was again
inferred as previously, i.e. higher levels of OPN, CXCL1-3, and
CXCL10 added to the combined disease score, while higherCell Reports 16, 2928–2939, September 13, 2016 2933
levels of CCL2 decreased the score. We found that the com-
bined regression score for proteins in CSF separated patients
and controls with a high accuracy (AUC = 0.79, p = 3.8 3
103; Figure 4B).
A critical factor in clinical management is prediction of disease
activity. At 2-year follow-up, 12 patients had no evidence of dis-
ease activity (NEDA) (Rotstein et al., 2015), while 27 had signs of
it (non-NEDA). We then tested if our combined score of these
four proteins, as measured in CSF (Table S5) at baseline, was
able to distinguish patients with or without disease activity by
displaying the disease probability scores. We found that the
combined score in CSF at baseline was able to predict NEDA af-
ter 2 years with high accuracy (AUC = 0.84, p = 9.6 3 104;
Figure 4C).
Module Proteins Can Distinguish Low and High
Responders to Treatment
Another aspect of personalized treatment is the possibility of
predicting response to treatment. We therefore tested, in a third
cohort of patients, whether our combined score in CSF (Table
S5) could also be used to distinguish subsequent high (n = 6)
and low (n = 9) responders to natalizumab, a commonly used
drug for MS, which targets a4-integrin and blocks entry of lym-
phocytes into the CNS (Mellerga˚rd et al., 2013). Since natalizu-
mab is one of the most effective MS drugs in use (Tramacere
et al., 2015), the low responders constitute a minor group (Gus-
tafsson et al., 2014; Mellerga˚rd et al., 2010) that was defined
by having one (n = 7) or two (n = 1) relapses during the first
year of treatment or having two relapses during 3 years of treat-
ment (n = 1). Although choosing this treatment is based on
several considerations, we reasoned that this cohort (Gustafs-
son et al., 2014; Mellerga˚rd et al., 2010), while very small, could
indicate the potential for predicting responses to treatment. For
these samples we lacked CXCL1-3 values so we re-trained our
original model without this protein on the 41 patients with early
MS. Remarkably, we found that the combined score obtained
in CSF before start of treatment was able to separate high and
low responders with high accuracy (AUC = 0.89, p = 0.012; Fig-
ure 4D). AUC values for both the second cohort (disease activity)
and the third cohort (response to treatment) were not affected by
the difference in group size, which we tested by performing 1
million random balanced subsets. In contrast to CSF, the
combined protein score in plasma (Table S5) did not distinguish
any of the tested clinical groups (disease versus non-disease in
the primary and the second cohort, NEDA versus non-NEDA
in the second cohort, or high versus low response to treatment
in the third cohort).
TheModule Proteins Can Classify Patients and Controls
inOther AutoimmuneDiseases, but TheyCannot Predict
Disease Activity
Lastly, we asked if the ability of the four proteins to predict the
presence of disease and disease activity was limited to MS or
if it was relevant in other autoimmune diseases involving CD4+
T cells. To test this we measured the four proteins in serum
from patients diagnosed with early RA (n = 40) and systemic
lupus erythematosus (SLE, n = 43), as well as a new cohort of
healthy donors (n = 40). Similarly to the previous analyses in2934 Cell Reports 16, 2928–2939, September 13, 2016the MS cohorts, we performed logistic regression and assessed
the predicted probabilities with cross-validation (combined
scores are shown in Table S5). Interestingly, we found the
same relationship among the proteins as for the MS patients
(positive for CXCL1-3, CXCL10, and OPN, but negative for
CCL2) and a significant separation for both RA (AUC = 0.89,
p = 1.6 3 109) and SLE (AUC = 0.77, p = 2.0 3 105) with
respect to controls. However, when we tested the ability of
the combined proteins score to predict disease activity (defined
as DAS28 in RA andmSLEDAI in SLE; Table S5) at 2-year follow-
up, we found no significant correlation between the combined
protein score and DAS28 at 2-year follow-up (Spearman cor-
relation = 0.27, p = 0.13) for RA patients, nor between
mSLEDAI scores at 2-year follow-up and combined protein
score (Spearman correlation = 0.006, p = 0.97) in SLE patients.
Furthermore, there was no correlation between the combined
protein score and disease activity at inclusion in any of the two
cohorts (data not shown). In summary, this analysis suggests
the general relevance of using the identified combined biomarker
score for autoimmune diseases, but shows that the correlation to
disease activity seems to be limited to MS.
DISCUSSION
In the present study we demonstrated an aberrant response to
activation in CD4+ T cells from MS patients and found that a
set of differentially activated proteins can act as biomarkers in
MS. This was achieved by transcriptomic profiling of the dy-
namic response to activation in CD4+ T cells, which is in contrast
to previous studies based on transcriptomic profiling of unstimu-
lated cells. Using a combined protein score based on CSF levels,
we were able, in twoMS cohorts, to (1) classify patients and con-
trols, (2) predict evidence or no evidence of disease activity after
2 years, and (3) classify low and high responders to treatment.
Our results confirm that activation of CD4+ T cells is a central
process in MS pathogenesis, as suggested by previous GWAS
findings (Sawcer et al., 2011). Our findings also suggest that po-
tential biomarkers might be identifiable for personalized treat-
ment, which is highly needed given variable disease course
and responses to given treatments for MS.
In order to validate our approach, we confirmed that each step
increased the concordance with GWAS data, thereby perform-
ing an a posteriori validation using previous evidence supporting
MS relevance. Indeed, MS-GWAS genes, in contrast to GWAS
genes from two other autoimmune diseases, RA and T1D,
were highly enriched in the DR gene set. Next, based on co-
localization of the DR genes, we took a network-based approach
and identified functionally interconnected genes in a disease
module that was again highly enriched with MS genes. Our
finding that chemotaxis forms a prominent submodule was not
suggested by previous GWAS analyses, but could potentially
be regarded as an event downstream of cell activation. The
role of chemokines in MS is supported by several gene expres-
sion profiling studies of T cells (Corvol et al., 2008; Mayne
et al., 2004; Satoh et al., 2006). In addition, chemotaxis is a pre-
requisite for entry of CD4+ T cells to the CNS. From a clinical
perspective, the dysregulated chemokine response can be uti-
lized for biomarker identification since chemokines are often
measurable in plasma and CSF, in general at higher concentra-
tions than cytokines (Mellerga˚rd et al., 2010).
The general TCR-mediated stimulation, affecting all CD4+
T cells, was chosen because myelin-specific T cells are scarce
in the circulation (L€unemann et al., 2004). Furthermore, the
most relevant specificities of myelin-specific CD4+ T cells may
still be unknown, although recent progress may address this
issue (Ayoglu et al., 2016). We used both naive and memory
CD4+ T cells, since the memory fraction may contain disease-
associated memory cells and the naive fraction facilitates the
finding of activation-induced dysregulation. In addition, we and
others (Okuda et al., 2005) found no difference between patients
and controls in the distribution of naive and memory cells.
Of the six proteins selected for biomarker studies, two
(sTNFR-1 and NT-3) were not secreted by CD4+ T cells
in vitro, probably because the model was designed for detection
of gene expression and not protein secretion and levels may
have been below the detection limit. However, four proteins
could be measured as secreted products from CD4+ T cells,
and when combined, their secreted levels could be used to
distinguish patients from controls. Notably, three of the proteins
were chemokines. CXCL1 is downstream of Th17 and involved
in recruitment of granulocytes, a process that was recently high-
lighted in experimental autoimmune encephalomyelitis (EAE)
and MS, including a potential role as a biomarker (Rumble
et al., 2015). CXCL10 is induced by IFN-g and involved in the
recruitment of CXCR3+ Th1 cells. Although pertinent to Th1-
associated mechanisms, as well as findings of increased CSF
levels (Mellerga˚rd et al., 2010; Sørensen et al., 2002), the role
of CXCL10 as a biomarker in MS has not been fully explored (Va-
zirinejad et al., 2014). CCL2 contributed to the classifier, but was
associated with lower levels in patients compared with controls,
in patients with disease activity and in patients not responding to
natalizumab treatment. The levels of CCL2 are in line with other
reports in MS (Mahad et al., 2006; Sørensen et al., 1999) and
have a suggested beneficial role in neuroinflammation (Kwon
et al., 2015). Furthermore, a beneficial role of CCL2 is supported
by its role in (1) the recruitment and activation of Th2 cells (Ip
et al., 2006), (2) M2-associated fetal tolerance in pregnancy
(Gustafsson et al., 2008; Svensson et al., 2011), and (3) reduced
macrophage production of proinflammatory cytokines (Sierra-
Filardi et al., 2014). The fourth protein, OPN (SPP1), is a well-
known driver of Th1-and Th17-responses, which is associated
with MS through increased levels in both CSF (Bo¨rnsen et al.,
2011) and plasma (Shimizu et al., 2013).
A key finding is that a combined protein score of CXCL1-3,
CXCL10, CCL2, and OPN, measured in CSF, was able not only
to discriminate early MS from controls in a new cohort but also
to predict evidence of disease activity after 2 years, a most valu-
able finding when deciding treatment strategies. Other proteins
in CSF, such as CXCL13, have been suggested as prognostic
tools to predict disease activity (Khademi et al., 2011), but
show lower AUC (0.64) when identifying patients with clinically
isolated syndrome (CIS) developing definite MS within 2 years
(Brettschneider et al., 2010). Of note, the combined score of pro-
teins being able to predict disease activity was also able to
predict low or high response to treatment, which suggests that
proteins relevant to the disease process are also important forthe response to treatment, further strengthening the potential
use of the combined score in personalized treatment. It should
also be noted that the vast majority of MS patients do respond
to natalizumab and that other considerations, such as JC-virus
status, decide treatment preference. Combinations of bio-
markers to predict response to treatment have been evaluated
previously, for example the ability of certain gene triplets pre-
dicted response to interferon beta in MS patients with an AUC
ranging between 0.63 and 0.80 (Baranzini et al., 2015). Neverthe-
less, the present results clearly show a potential of the combined
disease score in predicting response to treatment. While all clear
biomarker results were based on protein levels in CSF, there
were no such findings for plasma levels of proteins. Returning
to the dysregulated dynamic response in CD4+ T cells, it is
logical that CSF displays an altered protein profile, since acti-
vated disease-associated T cells travel to and are enriched in
the CNS/CSF compartment, thus representing the dynamic
response in vivo. It would have been of interest to study the dy-
namic response in CD4+ T cells from both our response to treat-
ment cohort and early MS cohort, but this lies beyond the scope
of the current study. There has been an extensive search for bio-
markers in MS (Comabella and Montalban, 2014; Raphael et al.,
2015), although they were mainly tested to detect the presence
of disease or ongoing disease activity rather than to predict dis-
ease activity (Raphael et al., 2015). Our combination of proteins
performed well in relation to previous studies of biomarkers,
showing a unique potential to predict both disease activity and
response to treatment. Although we tested performance in
new independent cohorts, it is important to conduct further
testing in prospective studies before clinical implementation.
One potential limitation of the protein module is that we
selected proteins that could be measured by commercial prod-
ucts. Thus, other gene products in the module could further
contribute to the performance as a biomarker. Indeed, our study
clearly shows the principle that aberrations in the dynamic
response can be used to identify relevant pathways and bio-
markers. The identified biomarkers showed some general rele-
vance by distinguishing other autoimmune disease (RA and
SLE) from controls, while disease activity was not reflected.
Thus, the general principle of aberrant dynamic response should
first be specifically applied to each disease. It should be empha-
sized that although our combination of four proteins showed
excellent performance, it cannot be excluded that other bio-
markers, in particular reflecting the neurodegenerative compo-
nent of the disease, might add to the biomarker potential
(Modvig et al., 2015).
In summary, we showed a dysregulated dynamic gene
response in the activation process of CD4+ T cells in MS. The
dysregulated genes formed an interconnected gene module
with cell activation and chemotaxis as central components.
From this gene module, we could identify a set of proteins that
can bemeasured in CSF, and by using the combined information
from this protein set, we were able to classify patients from con-
trols, predict disease activity after 2 years, and distinguish low
and high responders to treatment. We conclude that our study
shows a useful principle for detecting aberrant dynamic re-
sponses to cell activation. The combined score of proteins holds
promise as a clinically useful biomarker in personalized MSCell Reports 16, 2928–2939, September 13, 2016 2935
treatment, and the proposed translational strategy is generally
applicable and could be used to identify biomarkers for other
diseases in which CD4+ T cells play an active role.
EXPERIMENTAL PROCEDURES
Patients and Controls
CD4+ T cells were isolated from 16 women diagnosed with definite relaps-
ing-remitting MS according to the McDonald criteria (Polman et al., 2011).
None of the patients had experienced a relapse within 3 months prior to
blood sampling or had received immunomodulatory or immunosuppressive
treatment for at least 2 months (one exception was intravenous immu-
noglobulin treatment given 15 days before treatment in one patient). 16
age-matched, healthy control women were recruited among blood donors
(Table 1). To validate the clinical classifying capacity at the protein level,
plasma and CSF from a second cohort of 41 patients with early MS was
used (Table 1). These patients were followed for 2 years and classified
into NEDA (Rotstein et al., 2015) or not. CSF was also collected from 11
matched healthy control subjects (Table 1). A third cohort was used to eval-
uate if biomarkers were able to predict response to natalizumab; pre-treat-
ment CSF samples were selected from nine patients that did not fully
respond to treatment. The high responders (n = 6) were matched according
to age and disability (Table 1). This study cohort has been described else-
where (Gustafsson et al., 2014; Mellerga˚rd et al., 2010, 2013). To investigate
the specificity of the findings to MS, patients diagnosed with two other
autoimmune diseases (RA and SLE) were also included. 43 cases classified
with SLE, according to the 1982 American College of Rheumatology classi-
fication criteria (Tan et al., 1982) and the 2012 SLICC criteria (Petri et al.,
2012), were selected from the cohort Clinical Lupus Register in North-
eastern Gothia (KLURING), previously described in detail (Ighe et al.,
2015), and were included and followed for 2 years. Disease activity was re-
corded using the SLE Disease Activity Index 2000 (SLEDAI-2K), which was
also modified (mSLEDAI) by the exclusion of laboratory items for hypocom-
plementemia and anti-dsDNA antibody binding (Gladman et al., 2002). The
RA cohort consisted of 40 patients with early RA (first joint swelling <
12 months ago), fulfilling the 1987 American College of Rheumatology clas-
sification criteria for RA (Arnett et al., 1988), who were recruited to ‘‘the
Swedish TIRA project’’ 2006–2009 (Sva¨rd et al., 2015). Serum samples
were drawn at the inclusion visit (prior to institution of disease-modifying
anti-rheumatic drugs) and stored at 70C. 29 (73%) tested positive for
agglutinating rheumatoid factor, and 31 (78%) had antibodies against cyclic
citrullinated peptides (anti-CCP2). Disease activity was assessed according
to the original ‘‘28-joint disease activity score’’ (DAS28 [Prevoo et al., 1995]).
At inclusion, DAS28 was available from 39 of the 40 cases. At the 2-year
follow-up, DAS28-scores were reported in 31 cases. A cohort of 40 healthy
blood donors was also included as control. All patients and controls were
recruited at the Linko¨ping University Hospital, and the studies were
approved by the regional ethics committee in Linko¨ping, Sweden. See Sup-
plemental Experimental Procedures for further details.
Sample Preparation
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood
by density centrifugation (Lymphoprep, Axis-Shield), placed in a freezing
container at 70C overnight, and subsequently transferred and stored in
liquid nitrogen until use. After thawing, CD4+ T cells were isolated by immuno-
magnetic positive selection according to the instructions provided by
the manufacturer (Miltenyi Biotec). The purity of the isolated CD4+ T cells
was > 96%, based on flow cytometry (Figure S1). See Supplemental Experi-
mental Procedures for details.
Cell Culture
Isolated CD4+ T cells were stimulated with 0.03 mg/ml anti-CD3 and anti-CD28
antibodies or cultured unstimulated at a density of 1 million cells/ml for 24 hr at
37C. Culture supernatants were collected and the cells were used for flow
cytometry or homogenized and lysed in buffer RLT Plus (QIAGEN) and stored
at 70C. See Supplemental Experimental Procedures for details.2936 Cell Reports 16, 2928–2939, September 13, 2016Flow Cytometry Staining and Analysis
CD4+ T cells were labeled with mouse anti-human CD4, CD45RA, CCR7/
CD197, and CD69 (all from BD Biosciences) prior to flow cytometry analysis.
To assess the viability, CD4+ T cells were stained with Annexin V and 7AAD
(BD Biosciences). Patients and controls responded similarly to anti-CD3/
CD28 stimulation, based on CD69 expression (Figure S1). Further, the propor-
tion of naive (CCR7+CD45RA+) and memory (CD45RA) CD4+ T cells did not
differ between patients and controls (Figure S1). See Supplemental Experi-
mental Procedures for details.
RNA Extraction and Microarray Analysis
Total RNA from CD4+ T cells was extracted using the Allprep DNA/RNA Micro
kit (QIAGEN), amplified and labeled using the Low Input Quick Amp Labeling
Kit (Agilent Technologies), and purified with RNeasy Mini Kit (QIAGEN) before
hybridized onto Agilent Sureprint G3 Human Gene Expression 8x60k arrays
(Agilent Technologies) using the Gene Expression Hybridization Kit (Agilent
Technologies). The arrays were scanned on an Agilent Microarray Scanner
(Agilent Technologies). Data extraction and quality control fulfillment was
performed with the Feature Extraction software v.10.7.3.1 (Agilent Technolo-
gies). The accession number for the datasets reported in this paper is GEO:
GSE78244. See Supplemental Experimental Procedures for details.
Module Identification
The module was constructed using a modified, more robust and CD4+ cell-
specific version of a previously described method (Barrena¨s et al., 2012; Gus-
tafsson et al., 2014), by identifying a disease module from the median over an
ensemble of modules. We used the human PPI database STRING (v.10
[(Szklarczyk et al., 2015]) and considered the interactions with confidence
scores (psij) above 0.7 between all included 14,543 proteins of the database.
We calculated an interaction weight wij by the geometric mean of p
s
ij and
(1  pCij), where pCij is the double-sided Pearson correlation p value between
gene i and gene j expressions in all samples. We then repeated the following
steps 100 times. (1) Realize a perturbed network by drawing a random matrix
rij with matrix elements uniformly in [0,1] and let each interaction be included in
the network if wij > rij. Then, preceding with steps similar as in Barrena¨s et al.
(2012) to (2) identify all maximal cliques of the network with size 3 or more, (3)
calculate enrichment of each cliques for differentially expressed genes (unad-
justed limma t test p < 0.05) by Fisher’s exact test for each clique. (4) Select all
cliqueswith p < 0.01 as differentially expressed, and (5) extract the set of genes
and interactions present in these differentially expressed cliques as one per-
turbed module. From the 100 modules we inferred the robust module as the
genes present in more than half of the runs and removed the genes with less
than twice as many interactions as a randomization module created with shuf-
fled input data. Lastly, we removed the singletons from the disease module,
i.e. genes with no connections.
Analysis of Cytokines and Chemokines
Quantification of NT-3 was performed using DuoSet ELISA reagents from R&D
Systems (DY267), as described elsewhere (Boij et al., 2012). Multiplex Bead
Technology (MILLIPLEX MAP Kit, Catalog No. HCYTOMAG-60K-11,
HSCRMAG-32K, and HBNMAG-51K, Millipore) was used to measure all other
cytokines and chemokines in the supernatant and CSF samples according to
the manufacturer’s description. See Supplemental Experimental Procedures
for details.
Classification of Patients and Controls
To investigate if the measured mRNA and proteins, selected from the module,
could be used to separate patients from controls in culture supernatants,
we used the following combined score: (OPNStim  OPNUnstim) + (CXCL1-
3Stim  CXCL1-3Unstim) + (CXCL10Stim  CXCL10Unstim)  (CCL2Stim 
CCL2Unstim). Area under ROC curve (AUC) value was calculated using the
perfcurve MATLAB function; p value was calculated using double-sided
Wilcoxon test. Bootstrap p values were calculated by performing 1,000
random selections of 3 positive and 1 negative proteins among a set of 8 con-
trol proteins (GM-CSF, IFNg, IL-10, IL-13, IL-17, CCL17, M-CSF, and CCL20).
The p values were estimated from the bootstrap distribution of AUC values ob-
tained for the random classifier. For the CSF we had no baseline to subtract,
and instead for each of the subjects we performed a leave-one-out regression
score by performing logistic regression of patient probability estimation
without that subject in the training. For the high and low responders to natali-
zumab treatment, we lacked CXCL1-3 values and therefore retrained the logis-
tic regression on the original 41 patients without this protein. Moreover, as
three subjects also lacked CXCL10 values, we imputed their values using
knnimpute MATLAB function with default settings.
Statistical Analysis
Gene expression microarray data were quantile normalized, and p values for
differential expression were calculated using t test from the LIMMA package
in R. The p values for protein measurements were calculated using Mann-
Whitney test. For set enrichment analysis of GWAS genes, p values were
calculated using one-sided Fisher’s exact test, using all genes measured on
the gene expression array with at least one assayed SNP mapped as closest
as background (n = 16,799). Analysis of correlation between disease activity
and combined proteins score in SLE and RA patients was performed using
Spearman rank correlation.
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